BioWorld-Insight-2002-05-13

No Abstract

No Abstract

The failure early this month of Ribozyme Pharmaceuticals Inc.'s Angiozyme in a Phase II trial as a monotherapy against Stage IV metastatic breast cancer was enough to feed another round in the sporadic, ongoing debate over angiogenesis inhibitors. (BioWorld Financial Watch)

No Abstract

No Abstract

No Abstract